newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Appoints John Bencich as Chief Financial Officer

  • AEON Biopharma, Inc. appointed John Bencich as its new Chief Financial Officer effective March 09, 2026.
  • Bencich brings over 25 years of experience, including recent leadership as CEO of Achieve Life Sciences and prior CFO roles at OncoGenex Pharmaceuticals, Integrated Diagnostics, Allozyne, and Trubion Pharmaceuticals.
  • He holds a Bachelor of Accountancy from the University of San Diego and an MBA from Seattle University.
  • CEO Rob Bancroft stated Bencich's capital markets expertise will strengthen AEON's financial strategy & support disciplined capital formation during critical regulatory milestones.
  • AEON is advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® to achieve accelerated & full-label U.S. market entry.
  • ABP-450 is the same botulinum toxin complex marketed by Evolus, Inc. as Jeuveau® for cosmetic indications & is manufactured by Daewoong Pharmaceutical in a cGMP facility approved by the FDA, Health Canada, & EMA.
  • The product holds biosimilar approval in India, Mexico, & the Philippines.
  • AEON holds exclusive development & distribution rights for ABP-450 therapeutic indications in the U.S., Canada, the EU, the UK, & certain other international territories.
  • The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually.
  • Forward-looking statements in the release address regulatory plans, development strategy, & anticipated capital formation but are subject to risks including regulatory outcomes & market conditions.